文献速递免疫规划传染病防控与疫情报告

肠道病毒A71型疫苗对儿童手足口病的有效性及接种后感染的疾病特征

Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection.
PubMed 文献 · Vaccine · 2024-03-02

基于唯一指定的传染病定点医院长期数据,采用检测阴性病例对照设计和多因素 logistic 回归分析 EV-A71 疫苗对手足口病的有效性,并评估接种与疾病特征的关联。完全接种对 EV-A71 所致手足口病有效性为 63.4%,部分接种为 51.7%,对 CV-A6、CV-A10 或 CV-A16 相关手足口病未观察到保护;完全接种者住院时间和病程短于未接种者(P < 0.05)。

要点

  • 完全接种 EV-A71 疫苗对 EV-A71 所致手足口病有效性为 63.4%,部分接种为 51.7%。
  • 12 个月内接种首剂者疫苗有效性更高,对 CV-A6、CV-A10 或 CV-A16 相关手足口病未观察到保护。
  • 完全接种者住院时间和病程短于未接种者(P < 0.05)。

核心结论

  • 研究结果重申需要继续开发多价疫苗或联合疫苗,并对引入优化疫苗接种策略有启示。

研究设计与样本

  • 基于唯一指定的传染病定点医院长期数据,采用检测阴性病例对照设计和多因素 logistic 回归模型分析 EV-A71 疫苗对手足口病的有效性。
  • 选取 4883 例住院患者进行疫苗有效性估计,2188 例住院患者进行疾病特征比较。
  • 采用广义线性回归模型评估既往接种与疾病特征的关联。

主要发现

  • 完全接种对 EV-A71 所致手足口病的疫苗有效性为 63.4%,部分接种为 51.7%。
  • 在 12 个月内接种首剂的病例中疫苗有效性更高。
  • 无论接种状态如何,对儿童 CV-A6、CV-A10 或 CV-A16 相关手足口病未观察到保护。
  • 完全接种病例的住院时间和病程短于未接种病例(P < 0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination has been proven effective against infection with enterovirus A71 (EV-A71) in clinical trials, but vaccine effectiveness in real-world situations remains incompletely understood. Furthermore, it is not clear whether previous vaccination will result in symptom attenuation among post-vaccinated cases. METHODS: Based on long-term data extracted from the only designed referral hospital for infectious diseases, we used a test-negative case-control design and multivariate logistic regression models to analyze the effectiveness of EV-A71 vaccine against hand, foot and mouth disease (HFMD). And then, generalized linear regression models were used to evaluate the associations between prior vaccination and disease profiles. RESULTS: We selected 4883 inpatients for vaccine efficacy estimations and 2188 inpatients for disease profile comparisons. Vaccine effectiveness against EV-A71-induced HFMD for complete vaccination was 63.4 % and 51.7 % for partial vaccination. The vaccine effectiveness was higher among cases received the first dose within 12 months. No protection was observed against coxsackievirus (CV) A6-, CV-A10- or CV-A16-associated HFMD among children regardless of vaccination status. Completely vaccinated cases had shorter hospital stay and disease course compared to unvaccinated cases (P < 0.05). CONCLUSIONS: These findings reiterate the need to continue the development of a multivalent vaccine or combined vaccines, and have implications for introducing optimized vaccination strategies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Duan X, Zhang L, Ding L, et al. Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection. Vaccine. 2024. PMID: 38433065. doi:10.1016/j.vaccine.2024.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。